KERX Keryx Biopharmaceuticals Inc.

6.95
+0.03  (0%)
Previous Close 6.92
Open 6.95
Price To book 31.59
Market Cap 825314105
Shares 118,750,231
Volume 864,848
Short Ratio 22.52
Av. Daily Volume 1,136,702

SEC filingsSee all SEC filings

  1. 8-K - Current report 171083337
  2. 8-K - Current report 171066649
  3. 8-K - Current report 17984501
  4. 424B5 - Prospectus [Rule 424(b)(5)] 17984497
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17984457

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Sept 5, 2014.
Auryxia
Hyperphosphatemia
(sNDA) PDUFA date November 6, 2017.
Auryxia
Iron deficiency anemia in non-dialysis dependent CKD patients

Latest News

  1. Here's Why These 3 Biotech Stocks Might Stop Rallying
  2. Keryx Biopharmaceuticals, Inc. (KERX) Catches Eye: Stock Jumps 5.9%
  3. Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : September 15, 2017
  4. Keryx Biopharmaceuticals Announces Changes to its Board of Directors
  5. Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017
  6. Keryx Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:KERX) : September 2, 2017
  7. Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : KERX-US : August 29, 2017
  8. Edited Transcript of KERX earnings conference call or presentation 27-Jul-17 12:00pm GMT
  9. ETFs with exposure to Keryx Biopharmaceuticals, Inc. : August 11, 2017
  10. Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : August 7, 2017
  11. Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuity’s 37th Annual Growth Conference on August 9, 2017
  12. 3 Biotech Stocks With Big News Coming
  13. Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017
  14. Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat
  15. Keryx Biopharma reports 2Q loss
  16. ETFs with exposure to Keryx Biopharmaceuticals, Inc. : July 27, 2017
  17. Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance
  18. 3 Beaten-Up Biotechs Bouncing Back in 2017 (Hint: One Is a Marijuana Stock)
  19. What to Expect from Keryx (KERX) this Earnings Season?
  20. Biotech Bulletin of the Week: Gilead Sciences, Inc. (GILD), Vertex Pharmaceuticals Incorporated (VRTX), and Keryx Biopharmaceuticals (KERX)

SEC Filings

  1. 8-K - Current report 171083337
  2. 8-K - Current report 171066649
  3. 8-K - Current report 17984501
  4. 424B5 - Prospectus [Rule 424(b)(5)] 17984497
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17984457
  6. 8-K - Current report 17984451
  7. 8-K - Current report 17909478
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17899527
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 17814507
  10. 8-K - Current report 17811788